Tissue And Organ Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Tissue Products, Preservation Solutions, Immunosuppressive Drugs), By Application (Organ Transplantation, Tissue Transplantation), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 18.62 Billion
CAGR (2026-2031)	8.91%
Fastest Growing Segment	Tissue Products
Largest Market	North America
Market Size (2031)	USD 31.07 Billion

Market Overview

The Global Tissue And Organ Transplantation Market will grow from USD 18.62 Billion in 2025 to USD 31.07 Billion by 2031 at a 8.91% CAGR. The tissue and organ transplantation market encompasses medical procedures wherein biological material is transferred from a donor to a recipient to restore function following organ failure. Market expansion is fundamentally supported by the escalating global prevalence of chronic conditions such as renal and cardiovascular diseases which necessitate replacement therapies. Additionally, market growth is bolstered by improved healthcare infrastructure and the increasing efficacy of immunosuppressive protocols that enhance post-surgical survival rates and long-term patient outcomes.

However, the industry faces a significant impediment regarding the critical shortage of available donor organs relative to growing waiting lists. This disparity creates a substantial bottleneck that severely restricts the total volume of procedures performed annually despite high clinical demand. According to the Global Observatory on Donation and Transplantation, in 2024, the total number of solid organ transplants performed globally was reported at 172,397 procedures. This statistic underscores the continuing challenge of supply constraints in meeting the escalating worldwide need for transplant interventions.

Key Market Drivers

Technological advancements in organ preservation and surgical techniques represent a primary engine for market development, significantly extending the viability of donor organs outside the body. Innovations such as normothermic machine perfusion allow organs to be kept in a functioning state during transport, thereby reducing ischemic injury and expanding the pool of transplantable organs to include those previously deemed marginal. This shift from static cold storage to dynamic preservation fosters higher utilization rates and supports complex logistics. According to TransMedics Group, Inc., October 2024, in the 'Third Quarter 2024 Financial Results', the company reported net revenue of $108.8 million, a surge attributed largely to the increased clinical adoption of their proprietary Organ Care System for liver, heart, and lung programs.

The escalating prevalence of chronic diseases, particularly end-stage renal disease and liver failure, continues to intensify the critical demand for biological replacement therapies. Lifestyle factors, aging demographics, and the rising burden of diabetes and hypertension are accelerating the rate at which patients reach terminal organ dysfunction, necessitating immediate transplant interventions. This persistent gap between the supply of donor grafts and the volume of patients requiring treatment creates a sustained pressure on healthcare systems to enhance procurement strategies. According to the Health Resources and Services Administration, March 2024, in the 'Organ Donation Statistics' overview, there were over 103,000 candidates on the national transplant waiting list, reflecting the severe accumulation of patients with chronic organ failure. Furthermore, according to the United Network for Organ Sharing, in 2024, the U.S. system achieved a historic milestone by performing over 46,000 transplants in the preceding year, indicating a robust effort to address this growing clinical need.

Download Free Sample Report

Key Market Challenges

The critical shortage of available donor organs serves as a primary constraint on the trajectory of the tissue and organ transplantation market. This scarcity creates a rigid ceiling on the total volume of procedures that can be executed, directly limiting the revenue potential for transplant centers and medical device manufacturers. Despite high clinical demand and improvements in surgical infrastructure, the market is unable to scale effectively because the essential biological components required for operations are not available in sufficient quantities. This supply-demand gap results in a forced stagnation of procedural growth, leaving a significant portion of the addressable patient population unserved.

The magnitude of this bottleneck is evident in recent data from major transplant networks which highlights the disparity between clinical need and resource availability. According to the Organ Procurement and Transplantation Network, in 2024, there were more than 103,000 candidates listed on the national transplant waiting list in the United States. This statistic demonstrates that the demand for transplant interventions far exceeds the available supply, mechanically restricting the market from expanding to meet the actual needs of the population. As a result, the industry faces a persistent cap on its functional capacity, preventing the realization of potential revenue that would otherwise be generated from these lifesaving procedures.

Key Market Trends

The rise of xenotransplantation using genetically modified organs is establishing a novel supply of graftable tissues to address the critical donor shortage. Biotech companies are utilizing gene-editing tools to modify porcine organs, eliminating antigens that cause rejection and inserting human regulators to ensure biocompatibility. This advancement moves transplantation beyond human-only donor dependence, offering a scalable solution for patients who otherwise face high mortality rates on waiting lists. According to eGenesis, February 2025, in the 'eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney' update, the company successfully completed its 2nd human transplant of a gene-edited kidney, demonstrating the clinical viability of this alternative source.

Simultaneously, the shift toward robotic-assisted and minimally invasive transplant surgeries is enhancing procedural precision and improving post-surgical recovery. The integration of advanced robotic systems allows surgeons to perform complex vascular anastomoses with superior dexterity compared to open techniques, minimizing complications and shortening hospital stays. This technological evolution improves clinical outcomes and expands eligibility for high-risk patients previously deemed unsuitable for conventional operations. According to Intuitive Surgical, January 2025, in the 'Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results' report, worldwide procedures performed with da Vinci surgical systems grew by approximately 17% in 2024, highlighting the accelerating adoption of these platforms in complex medical interventions.

Segmental Insights

The Tissue Products segment represents the fastest-growing category within the Global Tissue And Organ Transplantation Market, primarily driven by the increasing demand for regenerative solutions in orthopedics and wound care. Unlike whole organs, these products benefit from advanced preservation techniques that enable long-term storage and wider distribution. This accessibility supports the treatment of a rising volume of sports injuries and severe burns requiring bone and skin grafts. Furthermore, established safety standards from organizations like the American Association of Tissue Banks enhance clinical confidence, thereby accelerating the adoption of tissue-based therapies over traditional autograft procedures.

Regional Insights

North America maintains the leading position in the global tissue and organ transplantation market due to its highly developed healthcare infrastructure and established donor networks. This regional dominance is driven by comprehensive reimbursement frameworks that facilitate patient access to transplantation procedures. Additionally, the rising incidence of chronic diseases leading to organ failure creates consistent demand for therapeutic solutions. The market also benefits from stringent oversight by the U.S. Food and Drug Administration, ensuring the safety of tissue products and devices. These structural and regulatory advantages collectively support the region's continued market leadership without relying on temporary trends.

Recent Developments

• In October 2024, CareDx and Dovetail Genomics announced a strategic partnership to drive innovation in the global tissue and organ transplantation market through advanced genomic solutions. The collaboration focused on combining Dovetail’s LinkPrep Hi-C technology with CareDx’s AlloSeq Tx HLA typing solution to enhance the precision of donor-recipient matching. By enabling the haplotyping of the entire HLA region, this joint effort aimed to provide transplant laboratories with superior tools for assessing histocompatibility. The partnership underscored the industry's commitment to leveraging next-generation sequencing to improve long-term survival rates for patients undergoing organ and stem cell transplantation.
• In October 2024, Paragonix Technologies received 510(k) clearance from the U.S. Food and Drug Administration for its KidneyVault Portable Renal Perfusion System, introducing a new standard for kidney preservation. This device was developed to provide a controlled, hypothermic environment for donor kidneys during transport, offering an alternative to traditional static cold storage methods. The regulatory approval marked a key product launch in the global tissue and organ transplantation market, expanding the company’s portfolio of organ-specific technologies. The system is designed to help maintain organ viability and streamline logistics for transplant centers.
• In August 2024, Getinge entered into a definitive agreement to acquire Paragonix Technologies for an estimated aggregate purchase price of $477 million to expand its presence in the organ preservation sector. This strategic acquisition allowed the company to integrate Paragonix’s advanced organ transport products and services, which are designed to preserve organ quality during transit, into its broader portfolio of acute care therapies. The transaction reflected a significant consolidation trend within the global tissue and organ transplantation market, driven by the increasing demand for technologies that improve donor organ utilization and transplant outcomes.
• In March 2024, eGenesis achieved a historic milestone in the global tissue and organ transplantation market by announcing the world’s first successful transplant of a genetically engineered porcine kidney into a living patient. The procedure was authorized by the FDA under the Expanded Access pathway and was performed at a major medical center. The proprietary EGEN-2784 kidney used in the surgery featured multiple genetic modifications designed to eliminate harmful pig antigens and inactivate endogenous retroviruses to ensure human compatibility. This breakthrough research highlighted the potential of xenotransplantation to address the critical shortage of human donor organs available for therapeutic use.

Key Market Players

• Artivion, Inc
• Folio Biosciences LLC
• Arthrex, Inc.
• Abbvie Inc.
• Zimmer Biomet Holdings, Inc.
• India Medtronic Private Limited
• Novartis AG
• Stryker Corporation
• BiolifeSolutions Inc.
• Teva Pharmaceutical Industries Ltd.

By Product	By Application	By Region
Tissue Products Preservation Solutions Immunosuppressive Drugs	Organ Transplantation Tissue Transplantation	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Tissue And Organ Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tissue And Organ Transplantation Market, By Product:

• Tissue Products
• Preservation Solutions
• Immunosuppressive Drugs

• Tissue And Organ Transplantation Market, By Application:

• Organ Transplantation
• Tissue Transplantation

• Tissue And Organ Transplantation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE